ERBB2 and breast cancer: The hazard of BC progression was greater among patients with higher DNAm at cg17735983, a probe mapping to MZF1. MZF1 is involved in the signaling pathways of HER2+ BC and implicated in development of more aggressive BC (Brix et al., 2020).